Nuveen’s Avita Medical RCEL Stock Holding History

Nuveen’s Portfolio RCEL Stock Details RCEL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,389	Closed	-$157K	–	3828
2026 Q1	$157K	Buy	42,389 +427	+1%	+$1.79K	﹤0.01%	3136
2025 Q4	$145K	Hold	41,962	–	–	﹤0.01%	3188
2025 Q3	$214K	Sell	41,962 -17,354	-29%	-$90.5K	﹤0.01%	3141
2025 Q2	$314K	Sell	59,316 -12,422	-17%	-$90.4K	﹤0.01%	3033
2025 Q1	$584K	Hold	71,738	–	–	﹤0.01%	2853
2024 Q4	$918K	Hold	71,738	–	–	﹤0.01%	2748
2024 Q3	$769K	Hold	71,738	–	–	﹤0.01%	2861
2024 Q2	$568K	Hold	71,738	–	–	﹤0.01%	2944
2024 Q1	$1.15M	Hold	71,738	–	–	﹤0.01%	2641
2023 Q4	$984K	Hold	71,738	–	–	﹤0.01%	2739
2023 Q3	$1.05M	Sell	71,738 -13,260	-16%	-$224K	﹤0.01%	2559
2023 Q2	$1.45M	Buy	+84,998	New	+$1.25M	﹤0.01%	2492
2022 Q2	–	Sell	-73,768	Closed	-$571K	–	3446
2022 Q1	$571K	Buy	73,768 +540	+0.7%	+$4.98K	﹤0.01%	2977
2021 Q4	$862K	Sell	73,228 -4,585	-6%	-$69.9K	﹤0.01%	2903
2021 Q3	$1.45M	Sell	77,813 -4,354	-5%	-$82.2K	﹤0.01%	2819
2021 Q2	$1.69M	Buy	+82,167	New	+$1.62M	﹤0.01%	2787

Other funds holding RCEL

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen's RCEL Position: Q2 2026 in Review

Nuveen sold out of Avita Medical (RCEL) in Q2 2026, closing a stake of 42,389 shares — an estimated $157K sold.

Nuveen first reported a position in RCEL in Q2 2021 and held it in 16 quarters. The position peaked at $1.69M in Q2 2021. 74 funds tracked by Wall St. Rank hold RCEL as of Q2 2026.

Nuveen reported no remaining Avita Medical position as of Q2 2026 after selling out during the quarter.
Nuveen sold 42,389 Avita Medical shares in Q2 2026, an estimated $157K.
Nuveen first reported a position in Avita Medical in Q2 2021 and held it in 16 quarters.
Nuveen's Avita Medical position peaked at $1.69M in Q2 2021.
74 funds tracked by Wall St. Rank held Avita Medical as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.